A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCAGN 1949-201

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 54828-101

To Learn More Call
201-510-0910

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
201-510-0910